Cargando…
Medicare Part B Spending on Macular Degeneration Treatments Associated With Manufacturer Payments to Ophthalmologists
IMPORTANCE: Age-related macular degeneration (ARMD) therapies aflibercept and ranibizumab are among the highest-cost Medicare Part B drugs, even though off-label use of lower-cost bevacizumab is clinically noninferior. Payments from manufacturers of these ARMD therapies to ophthalmologists are hypot...
Autores principales: | Dickson, Sean R., James, Katelyn E. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Medical Association
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10492178/ https://www.ncbi.nlm.nih.gov/pubmed/37682553 http://dx.doi.org/10.1001/jamahealthforum.2023.2951 |
Ejemplares similares
-
Spending on and Use of Clinician-Administered Drugs in Medicare
por: Hyland, Megan F., et al.
Publicado: (2023) -
Trends in Proportion of Medicare Part D Claims Subject to 340B Discounts, 2013-2020
por: Dickson, Sean, et al.
Publicado: (2023) -
Comparison of Out-of-Pocket Spending on Ultra-Expensive Drugs in Medicare Part D vs Commercial Insurance
por: DiStefano, Michael J., et al.
Publicado: (2023) -
Evaluation of Spending Differences Between Beneficiaries in Medicare Advantage and the Medicare Shared Savings Program
por: Parikh, Ravi B., et al.
Publicado: (2022) -
Comparison of Generic Prescribing Patterns Among 340B-Eligible and Non-340B Prescribers in the Medicare Part D Program
por: Dickson, Sean, et al.
Publicado: (2023)